LBLTF (Lattice Biologics) Receivables Turnover: 0.00 (As of Jun. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lattice Biologics Receivables Turnover?

Lattice Biologics LBLTF -99.00% Receivables Turnover is 0.00 as of Jun. 2021.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lattice Biologics's Revenue for the three months ended in Jun. 2021 was $0.00 Mil. Lattice Biologics's average Accounts Receivable for the three months ended in Jun. 2021 was $0.00 Mil.

Lattice Biologics  (OTCPK:LBLTF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Lattice Biologics Receivables Turnover Related Terms

Lattice Biologics Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Receivables Turnover Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.65 8.55 5.95 10.06 8.90

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 2.46 2.03 1.62 0.00

LBLTF vs ABT, MDT, SYK: Receivables Turnover Comparison

For the Medical Devices subindustry, Lattice Biologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lattice Biologics Receivables Turnover vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Receivables Turnover falls into.


Lattice Biologics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Lattice Biologics's Receivables Turnover for the fiscal year that ended in Sep. 2020 is calculated as

Receivables Turnover (A: Sep. 2020 )
=Revenue / Average Accounts Receivable
=Revenue (A: Sep. 2020 ) / ((Accounts Receivable (A: Sep. 2019 ) + Accounts Receivable (A: Sep. 2020 )) / count )
=2.464 / ((0.264 + 0.29) / 2 )
=2.464 / 0.277
=8.90

Lattice Biologics's Receivables Turnover for the quarter that ended in Jun. 2021 is calculated as

Receivables Turnover (Q: Jun. 2021 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2021 ) / ((Accounts Receivable (Q: Mar. 2021 ) + Accounts Receivable (Q: Jun. 2021 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
Lattice Biologics (LBLTF) has a Receivables Turnover of 0.00 as of Jun. 2021. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' Receivables Turnover too high?
Lattice Biologics' current Receivables Turnover is 0.00.
How does Lattice Biologics' Receivables Turnover compare to ABT and MDT?
Lattice Biologics' Receivables Turnover of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Receivables Turnover is 5.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lattice Biologics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lattice Biologics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Receivables Turnover is 0.00 as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.